Zhen Su, CEO at Marengo Therapeutics, shared a post on LinkedIn:
“We’re excited to announce the second Phase II clinical study for the Invikafusp alfa (Invika) program—evaluating the combination of Invika with Trodelvy (Trop-2–directed ADC) in metastatic breast cancer.
This study leverages the synergistic mechanism of action of the two therapies:
- Tumor-targeted ADC to debulk tumors and induce immunogenic cell death
- Invika to activate and expand fresh Vβ6 T cells in vivo, reinvigorating the anti-tumor immune response
We are deeply grateful to our clinical investigators, our partner at Gilead Sciences oncology and the patients who place their trust in us for this important study.
Study link.
Looking forward to a successful Phase II and the potential to bring new options to people living with breast cancer.”
More from Zhen Su on OncoDaily.